Clinical trial
A Double-blind, Randomized, 6-sequence, 3-period, Crossover Drug Drug Interaction Study to Evaluate the Pharmacokinetics of Wellbutrin SR and GSK189075 When Co-administered or Administered Alone in Healthy Male Volunteers
NCT00625859 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, 6-sequence, 3-period, Crossover Drug Drug Interaction Study to Evaluate the Pharmacokinetics of Wellbutrin SR and GSK189075 When Co-administered or Administered Alone in Healthy Male Volunteers
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 16, 2008
- Completion date
- April 10, 2008
- Enrollment
- 27 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.